Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria E Rodriguez

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Oncotarget|May 2, 2019
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsLeah A Mitchell, Kader Yagiz, Andrew Hofacre, et al.
Journal for Immunotherapy of Cancer|August 30, 2024
NKG2C/<i>KLRC2</i> tumor cell expression enhances immunotherapeutic efficacy against glioblastomaOlaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Ophthalmology|January 24, 2017
Concordance Between Clinical and Histopathological Diagnoses of Corneal SpecimensChristopher K H Burris, Amir A Azari, Ralph C Eagle, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2021
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeuticIñaki Etxeberria, Elixabet Bolaños, Alvaro Teijeira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular TrapsAlvaro Teijeira, Saray Garasa, Maria C Ochoa, et al.
Nature Medicine|February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaKurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Oncotarget|May 2, 2019
PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor modelsLeah A Mitchell, Kader Yagiz, Andrew Hofacre, et al.
Journal for Immunotherapy of Cancer|August 30, 2024
NKG2C/<i>KLRC2</i> tumor cell expression enhances immunotherapeutic efficacy against glioblastomaOlaya de Dios, M Angeles Ramírez-González, Irene Gómez-Soria, et al.
Journal for Immunotherapy of Cancer|February 11, 2025
4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor modelsEneko Garate-Soraluze, Irantzu Serrano-Mendioroz, Leticia Fernández-Rubio, et al.
Ophthalmology|January 24, 2017
Concordance Between Clinical and Histopathological Diagnoses of Corneal SpecimensChristopher K H Burris, Amir A Azari, Ralph C Eagle, et al.
Molecular Cancer|March 23, 2024
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancerAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Signal Transduction and Targeted Therapy|March 18, 2025
Monocyte-lineage tumor infiltration predicts immunoradiotherapy response in advanced pretreated soft-tissue sarcoma: phase 2 trial resultsAntonin Levy, Daphné Morel, Matthieu Texier, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 26, 2021
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeuticIñaki Etxeberria, Elixabet Bolaños, Alvaro Teijeira, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular TrapsAlvaro Teijeira, Saray Garasa, Maria C Ochoa, et al.
Nature Medicine|February 12, 2019
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastomaKurt A Schalper, Maria E Rodriguez-Ruiz, Ricardo Diez-Valle, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Pageof 8